WO1994014068A1 - Procede et dispositif d'analyse concernant le vih - Google Patents

Procede et dispositif d'analyse concernant le vih Download PDF

Info

Publication number
WO1994014068A1
WO1994014068A1 PCT/US1993/012154 US9312154W WO9414068A1 WO 1994014068 A1 WO1994014068 A1 WO 1994014068A1 US 9312154 W US9312154 W US 9312154W WO 9414068 A1 WO9414068 A1 WO 9414068A1
Authority
WO
WIPO (PCT)
Prior art keywords
reaction
compartment
waste
filter
compartments
Prior art date
Application number
PCT/US1993/012154
Other languages
English (en)
Inventor
Charles B. Beal
Henry Tom
Yacine Kouyate
Original Assignee
Empyrean Diagnostics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Empyrean Diagnostics Inc. filed Critical Empyrean Diagnostics Inc.
Priority to AU59513/94A priority Critical patent/AU5951394A/en
Publication of WO1994014068A1 publication Critical patent/WO1994014068A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/505—Containers for the purpose of retaining a material to be analysed, e.g. test tubes flexible containers not provided for above
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing

Definitions

  • This invention relates generally to the performance of medical diagnosis using transparent flexible envelopes and particularly to immunoassay analysis for HIV using transparent flexible envelopes.
  • the prior art discloses a variety of devices for handling, processing, and testing of chemical, biological, or medical specimens within transparent, compartmented containers.
  • Such devices include flexible, tubular containers having a series of individual compartments within which reagents may be contained and isolated until a specimen to be analyzed is added to the device. It is also known to provide means for manipulating such devices to permit specimens and/or reagents to seguentially react within the same or successive compartments.
  • a specimen may be added to a first compartment containing a first reagent and allowed to react with such first reagent.
  • the analyst may observe the reaction, and by color changes, precipitants, or other observable changes determine charactistics of the specimen.
  • the device may be manipulated to permit the specimen to pass from the first compartment to successive compartments and to react with successive reagents for subsequent observations.
  • Immunoassay analysis consists of exposing samples to antigens which will bind to the antibodies and then detecting the presence of the antibodies by using enzyme immunoassay detection systems.
  • This invention provides an improved method and device for immunoassay analysis by means of a flexible plastic pouch that is permanently sealed around its perimeter and is divided into one or more reaction compartments and one or more waste compartments.
  • the invention provides a method and device for immunoassay analysis for HIV antibodies, that may be performed on whole blood.
  • the device is provided with apertures adapted for the insertion of straws or other channels (herein referred to generically as “the straw or straws”) which act as passages for introducing reagents and specimens into the device.
  • the device is provided with means, such as a filter, for retaining certain components of the reaction products within the reaction compartment and permitting other components to pass into the waste compartment.
  • Immunoassay tests are performed by opening the sealed pouch to insert a straw or straws and positioning said straw so that its lower end provides access to any reagents or filter within the reaction compartment. External reagents are then passed through the straw to permit reaction with the filter or reagent and prepare the filter and/or reagent for a subsequent reaction with the specimen.
  • the specimen and, where appropriate, additional reagents are sequentially added to the reaction compartment through the straws until the reaction to be observed is complete.
  • waste products of the reactions such as wash solutions, excess reactants, and spent reactants are permitted to pass into the waste chamber through the filter.
  • the device After completion of the analysis, the device is sealed to contain the specimen and reactants so that the entire device may be disposed of safely.
  • FIG. 1 is a view of the preferred embodiment of a device in accordance with this invention with a flexible filter device within a single reaction compartment.
  • FIG. 2 is a side view of the device of FIG. 1 after insertion of slotted straws and a reagent tablet.
  • FIG. 3 is a view of an embodiment of the invention, containing two reaction compartments.
  • FIG. 4 is a view of an embodiment of the invention substituting a reagent for the filter device of the preferred embodiment.
  • FIG. 5 is a view of an embodiment of the invention substituting a rigid filter for the flexible filter device of the preferred embodiment.
  • FIG. 6 is a plan view of an embodiment of the invention comprising two devices within a supporting rack with a flow control clamp affixed.
  • FIG. 7 is a view of an embodiment of the invention, containing two separate reaction compartments and a common waste compartment having a compressed absorbent sponge therein.
  • FIG. 8 shows front and side views respectively of a rigid channel for adding reactants and sample.
  • FIG 1. A preferred embodiment of this invention is shown in FIG 1. in which a transparent, flexible, rectangular shaped pouch 2 is shown.
  • the device as shown is 7 inches long and 1 1/4 inches wide.
  • Pouch 2 is formed by thermally sealing two pieces of a thin flexible material, such as clear polyester, approximately 0.00142 inches thick to each other at their sides and bottom by perimeter seal 4. This results in an internal space positioned between the opposing interior faces of the original flexible material which constitutes pouch 2.
  • Pouch 2 is divided into reaction compartment 8 and waste compartment 12 by filter 10 which extends horizontally across the middle of pouch 2 and is thermally sealed to the front and back of pouch 2.
  • Filter 10 is a flexible transparent thermoplastic filter with approximately 12 micron pores and is approximately 0.00048 inches thick. As shown in FIG.2, filter 10 is V-shaped, with the apex of the V extending downward.
  • Interior seals 6 originate near the top of pouch 2 at perimeter seals 4 and extend downward and inward in a funnel shape to traverse filter 10, encompassing a portion of it within the seals and ending approximately 1 cm. below the filter.
  • the portion of interior seals which extends below the filter forms a one-way valve 14, which is the entry into waste compartment 12.
  • Waste compartment 12 contains a partial partition 16, fabricated from a flexible film having multiple perforations. Partition 16 extends upward from the bottom of waste compartment 12, but is not connected to the top of said compartment. It is attached to the pouch at perimeter seals 4 and the lower end of interior seals 6.
  • label 18 Attached to the top of the exterior of and extending above each face of pouch 2 are adhesive backed waterproof labels 18 which extend approximately 7 mm above each face.
  • the exposed adhesive surfaces of label 18 are covered with non-adhesive label liners 20, which extend 3 mm above the upper edge of each label, and the lower margins of which contact the upper margins of each face of the pouch.
  • FIG. 3 is a modification of the device in which a midline vertical seal 28 is added to form parallel testing areas. A straw is placed in each of the two triangular chambers thus formed. The filter is also bisected vertically. This permits the performance of simultaneous tests.
  • FIG. 4 is a variation of the invention, in which the filter is omitted and replaced by an antigen or antibody coated disc 30.
  • Disc 30 may be constructed of rigid material such as polystyrene or of porous membrane, such as nitrocellulose.
  • the antibody is not chemically bound, but when dry is permanently adsorbed into the surface or in the interstices.
  • the disc may be placed at the time of manufacture or added by a technician at the time of use. It is known to use discs of various kinds for the performance of an Enzyme Linked Immunosorbent Assay (ELISA) , however in conventional applications, a small spot of antibody or antigen is placed on the disc. In contrast, the entire surface of the disc used in this embodiment is coated to bind a maximum amount of conjugate, which in turn presents a broad surace to react with the substrate.
  • ELISA Enzyme Linked Immunosorbent Assay
  • FIG. 5 is another embodiment of the invention in which a cylindrical rigid filter 32 replaces the flexible filter of the preferred embodiment.
  • the filter may be constructed of cellulose and must have longitudinal pores of a smaller diameter than the reagent beads, described below, which will rest on top of the rigid filter during the test.
  • FIG. 6 is a plan view of a double pouch embodiment of the device in which the pouches are attached to support 40 having a base 42.
  • the pouches are held in place by clips 44.
  • a clamp 46 is provided which is attached to the pouches and may be opened and closed to regulate the flow of reagents within the pouches.
  • Straws 48 with broad slots 49 permit observation of the fluid passing down the straws.
  • Pouches 50 may be separated by tearing them apart at perforations 52.
  • FIG. 7 is a single pouch embodiment in which the perforated membrane as described in FIG. 2 has been eliminated and a compressed sponge 54 is positioned within the waste compartment. Sponge 54 serves to absorb and contain waste material.
  • FIG. 8 illustrates a variation of the straw insertion device.
  • the slotted straw is replaced by a V- shaped trough or channel which has the advantage of less surface contact with the pouch than a rounded straw. With less surface contact, there is likely to be less upward wicking of the liquid sample and reagents.
  • EIA Enzyme Immunoassay
  • ELISA Enzyme Linked Immunosorbent Assay
  • nitrocellulose membrane filters for the adsorbtion of the antigen or antibody, with the test generally performed by passing the usual reagents through the filter.
  • Microbeads, such as used in the present invention may also be used in various other configurations to obtain similar results.
  • reagents are provided in the form of 5 dry tablets which contain the following ingredients: TABLET KWash)
  • Bovine serum albumin azide 3-[N- morpholino] propanesulfonic acid (MOPS)
  • MOPS propanesulfonic acid
  • This tablet is used for the preparation of Wash Solution 1 and serves the purposes of filling the non-specific attachment areas of the beads, provided in Tablet 2, leaving free the areas designed for attaching antibodies.
  • the specific gravity of the solution is 1.014.
  • This tablet also aids in maintaining a pH of approximately 7.4 TABLET 2(Beads) Latex microspheres coated with HIV antigen, such as peptide chain gp 41 and p 24, plus mannose, glycine, and azide.
  • This tablet contains the microspheres, generally referred to as "beads", with antigen attachment points.
  • the specific gravity of the beads is 1.014.
  • This tablet contains the conjugate with anti-human antibodies, which attaches to the human antibodies, supplied by the blood samples, which have previously attached themselves to the antigens coating the beads in
  • This tablet is the source of the deter initive color change, when reacted upon by phosphatase in the conjugate splitting off the phosphate and causing a blue precipitate.
  • the reagents used in the usual above tests all can be purchased as commodity items. They consist of wash solutions composed primarily of salts and buffers, a conjugate composed of antihuman antibodies (if the test is to be performed on human serum or tissue) conjugated to an enzyme, and a substrate (developer) which can be acted upon by the enzyme, which then turns color. The intensity of the color is related to the amount of conjugate attached to the antigen or antibody as well as to the concentration of the substrate.
  • Pretesting preparations The various tablets are placed in dropper bottles and water is added to form solutions or suspensions.
  • Pouch 2 is hung on a suitable support, such as support 46 shown in FIG. 6.
  • Slotted drinking straw 24 is inserted into pouch 2 through the top of the pouch so that its lower end lies at the top of the upper part of the V-shaped end of Filter 10. The upper end of straw 24 protrudes about 1 inch above pouch 2.
  • a flow obstructing clamp 46 shown in FIG. 6 is placed over one way valve 14.
  • One drop of a blood sample to be tested is placed into straw 24 and then washed down with 5 drops of the Tablet 2 beads suspension which then remain within reaction compartment 10.
  • the now diluted blood sample is permitted to remain in contact with the beads for two minutes.
  • two drops of the conjugate solution are added to the diluted blood and beads mixture and allowed to react for 1 minute.
  • Clamp 46 is removed to allow the liquid to drain into waste compartment 12.
  • Two ml. of wash water are added to wash out all remaining blood. All visible traces of dye or blood must be eliminated.
  • Clamp 46 is then reapplied and three drops of the Tablet 4 substrate mixture are added. The sample is then observed for color changes. A blue color of the beads or in the liquid indicates the presence of HIV antibody in the blood sample. If no antibody is present, the fluid remains colorless. The test is stopped by the addition of two drops of the Tablet 5 stop solution.
  • the dye alone If instead of whole blood, serum is used as the sample, then the dye alone, present in the conjugate, colors the solution. Thus, all visible traces of the dye must be removed by washing prior to adding the substrate mixture.
  • a few drops of calcium hypochlorite are added.
  • the calcium hypochlorite kills any HIV virus particles that may be present.
  • the liners 20 of labels 18 are removed and the labels are pressed together, forming a water-tight seal. Pouch 2 may then be disposed of safely and without leakage.
  • a sample may be taken 1 hour or more before performing a test.
  • the blood sample may be placed in the pouch using a strip of nylon mesh.
  • the pouch is then closed and temporarily sealed by removing the liner from one of the labels and pressing that label against the opposite liner.
  • the blood sample clots in the mesh.
  • the serum then separates from the clot.
  • the pouch When the test is to be performed, the pouch is opened, the slotted straw is inserted, and five drops of the beads mixture is dropped into the filter through the straw. A clamp is applied and Tablet 1 Wash Mixture dropped in the pouch external to the straw to wash the serum down and bathe the beads, The test is then continued as described above.
  • the dimensions of the pouch may vary, as may the chemical formulation of the plastic film and filter.
  • the film and filter may vary in their physical characteristrics, such as thickness, flexibility, strength and pore size.
  • the reagents used may vary in chemical composition within the parameters of an EIA procedure.
  • the design of the pouch may be modified to accommodate more than 1 test simultaneously.
  • the pouch may be provided with a vertical center line seal and two straws used to perform two tests simultaneously as shown in FIG.3.
  • the waste compartment may be modified by removal of the midline vertical seal to form a common waste compartment as shown in FIG. 7. Also shown in FIG. 7 is compressed adsorbent sponge within the waste compartment to absorb and contain the waste material.
  • Another embodiment of the invention includes a filter, which instead of being sealed to the pouch on each face at the same level, is sealed to one face at a higher level than to the opposite face, producing a planar rather than a V-shape as in the preferred embodiment.
  • a clindrical rigid filter positioned in the pouch may be substituted for a flexible filter.
  • the filter may be eliminated and polystyrene or other absorbent membranes, or another type of disc containing absorbed antigen may be substituted for antigen coated beads.
  • the disc is placed in the pouch and comes to rest at the location of the filter in the preferred embodiment. The test is then performed in the same manner as described above for the filter version.
  • the perforated partition may be eliminated as shown in FIGS. 3,4,and 5, or it may be replaced by a compressed sponge as shown in FIG. 7.
  • test kit including pouches, straws and reagents can be produced at very low cost, enabling the product to be distributed at low cost. With very minimal modification, the kit can be used to perform a multiplicity of tests for infectious or other agents.
  • Another important advantage of the invention is the ability of the test to use whole blood, thus eliminating the need to start the test with serum or other processed blood derivitives.
  • the test will work with fresh whole blood, anticoagulated or clotted whole blood, serum, or plasma.
  • the Triton X67 a soluble surface-active agent destroys the red blood cells releasing hemoglobin into the solution, imparting a red color to the mixture of blood and beads during the blood/bead contact phase.
  • the hemoglobin does not interfere with the attachment of HIV antibody to the antigen on the surface of the beads. Since it is important to wash out excess antibody prior to adding conjugate, the loss of red color indicates that washing has been adequate.
  • the construction and function of the pouch permits the blood or serum specimen to be processed immediately after drawing, or to be placed in the pouch and processed up to several hours or 1-2 days after adding the specimen.
  • the inventors know of no other HIV diagnostic test that permits such a broad range of choices in handling the blood specimen.
  • the filter and the film are both constructed of thermoplastic polyester which allows a flexible filter to be incorporated in a flexible pouch by means of heat sealing, eliminating all rigid components in the pouch construction and use. This feature contributes to low cost manufacture and shipping, as each finished pouch weighs slightly more than three grams.
  • the slit straw allows both blood and reagents to be delivered directly to the filter, largely eliminating reagent seeping along the creases of the device. Further the slit provides an escape for air as fluid is added, preventing air lock. The slit effectively prevents the possibly contaminated straw from being used for purposes (such as drinking) other than for which it is intended.
  • the provision of dry reagents to be reconstituted just prior to use offers greatly enhanced shelf-life and significantly reduced costs when compared to devices in which liquid reagent is prepackaged in the device.
  • the present invention can be characterized as “bathe and drain,” the reagents first bathing the beads and then being drained, partly through the beads as in the flow-through design, and partly above the bead level.
  • This system allows for rapid removal of used reagents and wash solution, thus contributing to rapid completion of the test. It does not require the use of mechanical means, such as air pressure, which are often used to provide rapid passage of waste liquids through the flow through type bead column and cylindrical filter devices.
  • the beads while lying on the filter may be manipulated by hand or instrument through the face of the pouch to increase contact of the beads with the blood or reagents.
  • test can be used with commercially available non-carbonated bottled water, presently available in most areas of the world.
  • the conjugate tablet contains two dyes: safrinine, a red azine dye, and methylene blue, a triarylmethane dye.
  • the dyes have the following actions: together they impart a purplish tint to the tablet, serving as a color code to avoid confusion with other tablets used.
  • the polyester filter is safraninophilic, absorbing the red dye and giving the filter a red tint. This tint serves to form a useful contrasting background to the beads so as to better distinguish their color in determining the results of the test.
  • the methylene blue dye does not stain the filter but provides a blue color to the liquid from the dissolved conjugate tablet. Since it is important to remove all conjugate from the test area of the pouch before adding the developer, absence of blue color in the liquid indicates that adequate washing has occurred. Neither dye stains the beads nor interferes with the chemical reactions occurring in the test.
  • the labels not only provide a mechanism for patient identification and dates, but also both a temporary and permanent closure of the pouch.
  • the temporary closure is used when the test is to be performed several hours after drawing blood.
  • One drop of whole blood is placed within the pouch either directly, or on a strip of non- absorbable paper or mesh, such as nylon.
  • One label liner is removed and that label pressed against the opposite liner. Such action allows the blood to clot within the pouch but not to dry.
  • Disposal of the test device provides for user safety, by a permanent closure being accomplished by the removal of both liners of the labels and the pressing of the adhesive surfaces of the labels together.
  • a modification permits the performance of a multiplicity of tests, for example, for various antibodies or antigens within a single type of pouch.
  • the perforated partition in the waste compartment essentially changes its surface charactistics as the perforations eliminate flow resistance due to the static attraction of the inner surfaces of the device faces. This enhances the rate of flow from the filter into the bottom of the waste compartment, thus helping to eliminate upward wicking of the waste fluid, which could cause false positive tests if not prevented.
  • the absorptive sponge in the waste compartment serves the same purpose by first absorbing fluid entering the waste compartment and then expanding in thickness to separate the leaves of the pouch and eliminate static attraction of the leaves to each other.
  • it is desirable to control the specific gravity of the dissolved components of the bead mixture so that it's specific gravity is substantially the same as that of the undissolved beads. Such control assures a more homogeneous mixture in contrast to a mixture of differing densities in which the beads would either float or fall to the bottom and thus the resultant mixture would not be consistent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Clinical Laboratory Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

On décrit un procédé et un dispositif d'analyse par immuno-titrage en général et, en particulier, de détection par immuno-titrage d'anticorps au VIH dans le sang total. Ce dispositif comporte une poche en matière plastique souple à périmètre étanche en permanence, sauf au sommet, poche divisée en un ou plusieurs compartiments de réaction et un ou plusieurs compartiments à déchets. Ce dispositif comporte des ouvertures conçues pour recevoir des paillettes ou autres conduites destinées à l'introduction de réactifs et de spécimens. Il comporte en outre un élément, un filtre par exemple, devant retenir certains composants des produits de réaction dans le compartiment de réaction et permettre aux déchets produits par cette réaction de passer dans le compartiment à déchets. Après achèvement de l'analyse, ce dispositif est scellé de façon à confiner le spécimen et les réactifs, ce qui permet d'éliminer l'ensemble en toute sécurité.
PCT/US1993/012154 1992-12-15 1993-12-14 Procede et dispositif d'analyse concernant le vih WO1994014068A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59513/94A AU5951394A (en) 1992-12-15 1993-12-14 Hiv analysis method and device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99069892A 1992-12-15 1992-12-15
US990,698 1992-12-15

Publications (1)

Publication Number Publication Date
WO1994014068A1 true WO1994014068A1 (fr) 1994-06-23

Family

ID=25536443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/012154 WO1994014068A1 (fr) 1992-12-15 1993-12-14 Procede et dispositif d'analyse concernant le vih

Country Status (6)

Country Link
CN (1) CN1092867A (fr)
AP (1) AP434A (fr)
AU (1) AU5951394A (fr)
IL (1) IL108034A0 (fr)
WO (1) WO1994014068A1 (fr)
ZA (1) ZA939387B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0632894A1 (fr) * 1992-03-27 1995-01-11 Abbott Laboratories Methodes permettant d'obtenir des reactifs homogenes
WO2010080223A1 (fr) * 2008-12-18 2010-07-15 3M Innovative Properties Company Système et procédé de préparation d'échantillons
US8272255B2 (en) 2006-05-22 2012-09-25 3M Innovative Properties Company System and method for preparing samples
EP3421131A1 (fr) * 2017-06-30 2019-01-02 Blink AG Cartouche d'échantillon pour incubation et/ou analyse d'une dispersion de particules, de cellules ou de gouttelettes

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112082839A (zh) * 2020-09-29 2020-12-15 安徽国科生物科技有限公司 痰液标本采集机器人及其控制方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0255190A2 (fr) * 1986-08-01 1988-02-03 Repligen Corporation Polypeptides recombinants et leurs applications, ainsi qu'essai pour le virus du SIDA
EP0306206A1 (fr) * 1987-08-27 1989-03-08 Cogent Diagnostics Limited Dispositif d'essai et procédé
EP0480497A1 (fr) * 1990-10-08 1992-04-15 Akzo Nobel N.V. Appareil pour l'exécution d'un dosage à la main unique et rapide
EP0485228A1 (fr) * 1990-11-09 1992-05-13 Ortho Diagnostic Systems Inc. Essai d'agglutination en colonnes et dispositif

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0255190A2 (fr) * 1986-08-01 1988-02-03 Repligen Corporation Polypeptides recombinants et leurs applications, ainsi qu'essai pour le virus du SIDA
EP0306206A1 (fr) * 1987-08-27 1989-03-08 Cogent Diagnostics Limited Dispositif d'essai et procédé
EP0480497A1 (fr) * 1990-10-08 1992-04-15 Akzo Nobel N.V. Appareil pour l'exécution d'un dosage à la main unique et rapide
EP0485228A1 (fr) * 1990-11-09 1992-05-13 Ortho Diagnostic Systems Inc. Essai d'agglutination en colonnes et dispositif

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0632894A1 (fr) * 1992-03-27 1995-01-11 Abbott Laboratories Methodes permettant d'obtenir des reactifs homogenes
EP0632894A4 (fr) * 1992-03-27 1997-05-02 Abbott Lab Methodes permettant d'obtenir des reactifs homogenes.
US8272255B2 (en) 2006-05-22 2012-09-25 3M Innovative Properties Company System and method for preparing samples
US8991239B2 (en) 2006-05-22 2015-03-31 3M Innovative Properties Company System and method for preparing samples
WO2010080223A1 (fr) * 2008-12-18 2010-07-15 3M Innovative Properties Company Système et procédé de préparation d'échantillons
EP3421131A1 (fr) * 2017-06-30 2019-01-02 Blink AG Cartouche d'échantillon pour incubation et/ou analyse d'une dispersion de particules, de cellules ou de gouttelettes
WO2019002622A1 (fr) * 2017-06-30 2019-01-03 Blink Ag Cartouche d'échantillon pour incuber et/ou analyser une dispersion de particules, de cellules ou de gouttelettes
JP2020525022A (ja) * 2017-06-30 2020-08-27 ブリンク アーゲー 粒子、細胞、または液滴の分散体をインキュベートおよび／または分析するためのサンプルカートリッジ

Also Published As

Publication number Publication date
AU5951394A (en) 1994-07-04
AP9300600A0 (en) 1994-01-31
IL108034A0 (en) 1994-04-12
AP434A (en) 1995-11-17
ZA939387B (en) 1994-08-29
CN1092867A (zh) 1994-09-28

Similar Documents

Publication Publication Date Title
US5077012A (en) Device for detecting disease markers
US4833087A (en) Disposable container configured to produce uniform signal
US5185127A (en) Test device including flow control means
EP0556202B1 (fr) Analyse de detection amelioree de ligands
EP0319294B1 (fr) Examen de membrane utilisant l'application concentrée d'un échantillon
JP4040110B2 (ja) 膜ベースでの検定のための分析装置
CA2588420C (fr) Dispositif et procede destines a detecter des analytes
US7347972B1 (en) Multiple analyte assay device
EP0418765A2 (fr) Appareil d'analyse comportant des moyens de contrôle de flux
JPH01502054A (ja) 内蔵式の固相免疫拡散試金のための装置及び方法
JPH0616047B2 (ja) 必要物が完備したイムノアツセイ要素
JPS59153172A (ja) 核酸の定量装置
WO1987007304A1 (fr) Procede et systeme de detection de cellules
US4859421A (en) Disposable antigen concentrator and detector
US5817522A (en) Self-contained assay device and method
US5120504A (en) Apparatus for immunoassays with vent chennels in the container side wall
US5231035A (en) Latex agglutination assay
AP434A (en) HIV analysis method and device.
CA1104927A (fr) Traduction non-disponible
US8623291B2 (en) Multiple analyte assay device
NZ231893A (en) Dipstick for assaying viscous liquids or liquids containing cellular or particulate matter
EP0324603A2 (fr) Appareil pour immunoessai enzymatique en phase solide et procédé pour détecter les anticorps
EP0561003A1 (fr) Dispositif pour détecter des marqueurs de maladies
JP3007410B2 (ja) マルチウエルテスト
NO860937L (no) Diagnostikum for assaybestemmelser.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA